Business Standard

Sun Pharma at new high on FDA nod for generic version of Januvia

USFDA has granted its subsidiary, two tentative approvals for its ANDA for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Related News

Sun Pharmaceutical Industries has moved higher by 3% to Rs 914, extending its previous day’s 2.3% gain after the company said it has received a tentative approval from the US drug regulator for generic version of Januvia.

The stock opened at Rs 886 and hit a new high of Rs 920 on NSE. The trading volumes on the counter more than doubled with a  combined 699,849 shares changing hands till 1141 hours on NSE and BSE.

On Monday, said that the US Food and Drugs Administration (USFDA) has granted its subsidiary, two tentative approvals for its Abbreviated New Drug Applications (ANDA) for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Sitagliptin tablets have annual sales of approximately US$ 2.7 billion, while Metformin HCl Extended-release tablets have annual sales of approximately US$ 140 million in the US, it added.

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. Metformin HCl Extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.
 

Read more on:   
|
|

Read More

Fresenius Kabi Oncology soars on delisting plan

The promoter intends to pay an indicative price of Rs 130 per share to acquire the shares offered to it in the Delisting Offer

Recommended for you

Advertisements

Quick Links

Market News

Sensex sheds 499 pts; Bank of Baroda, ICICI Bank results disappoint

Coal India drops 4 per cent even as its Rs 22,000 crore offer for sale fully subscribed; Nifty sheds 143 pts

Coal India 10% stake sale fully covered

Investors bid for 662 million shares of Coal India versus the issue size of 631.6 million shares

Sensex ends below 29,200; BSE Bankex down 3%

The 30-share Sensex provisionally ended down by 482 points at 29,199 and the 50-share Nifty slipped 130 points at 8,823.

Strides Arcolab gains on USFDA OKs oral dosage facility at Bangalore

The stock was up 4% at Rs 933 on BSE.

ICICI Bank dips over 5% post Q3 results

At 1445 hours, the stock was down nearly 6% at Rs 358 on National Stock Exchange.

 

Back to Top